Samtidig administration af Thelin og Ortho- Novum 1/ 35 (1 mg norethindron / 0, 035 mg ethinylestradiol) resulterede i stigning i eksponering for ethinylestradiol (CYP3A4/ 5- substrat) og norethindron (CYP3A4/ 5) på henholdsvist 59% og 47%.
Concomitant administration of Thelin and Ortho- Novum 1/ 35 (1 mg norethindrone/ 0.035 mg ethinyl estradiol) resulted in increases in exposure to ethinyl estradiol (substrate of CYP3A4/ 5) and norethindrone (CYP3A4/ 5) of 59% and 47%, respectively.